ArticleBMC nephrology2025
Lupus nephritis association with idiopathic CD4 + T lymphocytopenia: a case report of a young man with recalcitrant warts.
Article in BMC nephrology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionSystemic lupus erythematosus (SLE) is an autoimmune disease in which the immune system is in a disordered state, with excessive production of autoantibodies and abnormal functions of immune cells. This imbalance in the immune system alters the body's defense capabilities against various pathogens. Patients with idiopathic CD4⁺ T lymphocytopenia (ICL) have a reduced number of lymphocytes, and the function of the immune system is also impaired. Human papillomavirus (HPV) infects human body and mainly lurks and replicates in skin and mucosal cells. CASE REPORT: A 35-year-old Chinese male was admitted to the Nephrology department, with a three-year history of recalcitrant warts and a six-month history of generalized edema and fatigue. Physical examination identified verruca vulgaris on the limbs and face. Laboratory examinations demonstrated CD4⁺ T lymphocytopenia, low levels of C3 complement, and positive antinuclear antibodies. Renal function tests indicated nephrotic syndrome. Renal biopsy findings were consistent with Class V lupus nephritis (LN). Based on the 2019 EULAR/ACR criteria, the patient was diagnosed with systemic lupus erythematosus (SLE) and treated with prednisone and tacrolimus. However, after six months, no remission was observed. With the administration of Belimumab, a significant improvement in his renal symptoms and stabilization of cutaneous lesions were noted at the 12-month follow-up.
conclusionThis particular case emphasizes the significance of taking into account the potential presence of underlying immunodeficiency in patients with recalcitrant warts and formulating appropriate treatment strategies. Such patients necessitate meticulous and continuous follow-up by both the dermatology and immunology specialties to vigilantly monitor the emergence of other diseases associated with ICL. Belimumab has manifested outstanding efficacy and safety profiles in SLE patients with compromised immune function.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.